ADAMTS-13 activity in stroke of known and unknown cause: Relation to vascular risk factor burden.
ADAMTS-13
biomarker
embolic stroke of undetermined source
patent foramen ovale
stroke etiology
thrombosis
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
09
2022
accepted:
13
12
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
The identification of the underlying mechanism in ischemic stroke has important implications for secondary prevention. A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS-13) has antithrombotic properties and was repeatedly implicated in the pathophysiology of stroke. In this study, we, therefore, aimed to investigate whether ADAMTS-13 is associated with stroke etiology and the burden of vascular risk factors. We determined ADAMTS-13 activity in two prospectively recruited stroke cohorts in the long-term course after the event. Cohort 1 ( ADAMTS-13 activity was lower in patients with AF-related stroke compared to patients with ESUS ( ADAMTS-13 activity is inversely correlated with the number of vascular risk factors across different stroke etiologies. Further study is warranted to establish ADAMTS-13 as a mediator of cerebrovascular risk.
Sections du résumé
Background
UNASSIGNED
The identification of the underlying mechanism in ischemic stroke has important implications for secondary prevention. A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS-13) has antithrombotic properties and was repeatedly implicated in the pathophysiology of stroke. In this study, we, therefore, aimed to investigate whether ADAMTS-13 is associated with stroke etiology and the burden of vascular risk factors.
Methods
UNASSIGNED
We determined ADAMTS-13 activity in two prospectively recruited stroke cohorts in the long-term course after the event. Cohort 1 (
Results
UNASSIGNED
ADAMTS-13 activity was lower in patients with AF-related stroke compared to patients with ESUS (
Conclusion
UNASSIGNED
ADAMTS-13 activity is inversely correlated with the number of vascular risk factors across different stroke etiologies. Further study is warranted to establish ADAMTS-13 as a mediator of cerebrovascular risk.
Identifiants
pubmed: 36703637
doi: 10.3389/fneur.2022.1045478
pmc: PMC9871749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1045478Informations de copyright
Copyright © 2023 Grosse, Leotescu, Sieweke, Schneppenheim, Budde, Ziegler, Biber, Gabriel, Ernst, Schuppner, Lichtinghagen, Bavendiek, Widder and Weissenborn.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Genet. 2021 Jul 01;12:660989
pubmed: 34276770
Neurology. 2018 Mar 20;90(12):e995-e1004
pubmed: 29444972
Stroke. 2015 Sep;46(9):2491-7
pubmed: 26304862
Stroke. 2017 Apr;48(4):867-872
pubmed: 28265016
Atherosclerosis. 2009 Nov;207(1):250-4
pubmed: 19439298
Front Neurol. 2021 Sep 22;12:719329
pubmed: 34630291
JAMA Netw Open. 2018 Sep 7;1(5):e182953
pubmed: 30646186
Stroke. 2018 Feb;49(2):412-418
pubmed: 29335335
Stroke. 2009 Feb;40(2):350-4
pubmed: 19023098
Front Neurol. 2021 Jan 15;11:606663
pubmed: 33519684
Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2446-2451
pubmed: 27737864
Int J Mol Sci. 2019 Feb 09;20(3):
pubmed: 30744089
Sci Rep. 2019 Dec 19;9(1):19424
pubmed: 31857660
J Am Coll Cardiol. 2020 Jan 28;75(3):333-340
pubmed: 31976872
Stroke. 2019 Nov;50(11):3184-3190
pubmed: 31526123
Stroke. 2020 Oct;51(10):3119-3123
pubmed: 32921262
N Engl J Med. 2017 Sep 14;377(11):1033-1042
pubmed: 28902580
Clin Res Cardiol. 2020 Feb;109(2):205-214
pubmed: 31236691
Ann Neurol. 2013 Jan;73(1):58-64
pubmed: 23225307
Cell Mol Life Sci. 2019 Aug;76(16):3117-3140
pubmed: 31165904
Front Neurol. 2020 Jul 31;11:799
pubmed: 32849241
Expert Rev Cardiovasc Ther. 2017 Aug;15(8):591-599
pubmed: 28718666
Front Neurol. 2021 Feb 25;12:624930
pubmed: 33716927
Thromb Haemost. 2018 Apr;118(4):758-767
pubmed: 29618156
Blood. 2016 May 12;127(19):2337-45
pubmed: 26929275
Front Neurol. 2019 Jul 17;10:772
pubmed: 31379722
Stroke. 2016 Sep;47(9):2278-85
pubmed: 27507859
Thromb Res. 2021 Jan;197:132-137
pubmed: 33212380
Blood. 2015 Dec 17;126(25):2739-46
pubmed: 26511134
Annu Rev Med. 2015;66:211-25
pubmed: 25587650
JAMA Neurol. 2020 Oct 1;77(10):1233-1240
pubmed: 32628266
Stroke. 2020 Jun;51(6):1797-1804
pubmed: 32295509
N Engl J Med. 2017 Sep 14;377(11):1011-1021
pubmed: 28902593
J Am Heart Assoc. 2019 Aug 6;8(15):e012858
pubmed: 31364451
N Engl J Med. 2017 Sep 14;377(11):1022-1032
pubmed: 28902590
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
J Am Coll Cardiol. 2016 Mar 1;67(8):907-917
pubmed: 26916479
Eur Stroke J. 2022 Jun;7(2):92-98
pubmed: 35647310
Neurology. 2013 Aug 13;81(7):619-25
pubmed: 23864310
Circulation. 2021 Nov 30;144(22):1738-1746
pubmed: 34649459
Stroke. 2020 Dec;51(12):3737-3741
pubmed: 33040704
Neurology. 2019 Dec 3;93(23):e2094-e2104
pubmed: 31662492
J Thromb Thrombolysis. 2020 Jan;49(1):67-74
pubmed: 31482326
Front Cardiovasc Med. 2021 Aug 09;8:674612
pubmed: 34434973
BMJ. 2022 Feb 9;376:e063161
pubmed: 35140114